CKD-828(80/2.5mg) Pharmacokinetic Study

Exclusion Criteria

• •Take metabolic enzyme inducing or inhibiting drugs like barbiturates within 28 days prior to the first IP administraion.
• •The evidence of acute disease within 28 days prior to the first IP administraion.
• •Disease(ex: imflammatory intestinal disease, gastric or duodenal ulcer ,hepatic diseasehistory , gastro intestinal surgery exept for appendectomy)that may influence on the absorption, distribution, metabolism and excretion of the drug(s).
• •Relevant hypersensitivity against drug or clinically significant allergic diseases except mild rhinitis that doesn't need medication.
• •Hypersensitivity Telmisartan or Amlodipine.
• •SBP\<90mmHg or DBP\<50mmHg.
• •Abnormal laboratory result(s): AST or ALT \> 1.25 times of upper limit / Total bilirubin \> 1.5 times of upper limit.
• •A drug abuse or a heavy caffeine consumer (more than 5 cups per a day) or a heavy smoker(more than 10 cigarettes per a day) or a regular alcohol consumer(more than 30g/day) or drinking within 7days prior to the first IP administration.
• •Diet(Especially, grapefruit juice-within 7 days prior to the first IP administraion) that may influence on the absorption, distribution, metabolism and excretion of the drug(s).
• •Donated whole blood within 60 days prior to the first IP administraion.
• •Participated in the other clinical trials within 90days prior to the first IP administraion.
• •Medicine within 10 days prior to the first IP administraion? Does the medication affect this trial.
• •A pregnant or nursing women who does not use medically acceptable birth control.
• •Appropriate for the trial judging from principal investigator.